DongKook Pharmaceutical Co., Ltd.

Informe acción KOSDAQ:A086450

Capitalización de mercado: ₩746.9b

DongKook Pharmaceutical Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de DongKook Pharmaceutical de 16.2% y 9.7% por año respectivamente. Se prevé que el BPA crezca en un 15.7% al año. Se espera que la rentabilidad financiera sea de 10.6% en 3 años.

Información clave

16.2%

Tasa de crecimiento de los beneficios

15.7%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals33.9%
Tasa de crecimiento de los ingresos9.7%
Rentabilidad financiera futura10.6%
Cobertura de analistas

Low

Última actualización19 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

We Think DongKook Pharmaceutical (KOSDAQ:086450) Can Stay On Top Of Its Debt

May 06
We Think DongKook Pharmaceutical (KOSDAQ:086450) Can Stay On Top Of Its Debt

DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Vies For A Place In Your Dividend Portfolio: Here's Why

Apr 06
DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Vies For A Place In Your Dividend Portfolio: Here's Why

How Much Of DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Do Insiders Own?

Mar 15
How Much Of DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Do Insiders Own?

The DongKook Pharmaceutical (KOSDAQ:086450) Share Price Has Gained 136%, So Why Not Pay It Some Attention?

Feb 28
The DongKook Pharmaceutical (KOSDAQ:086450) Share Price Has Gained 136%, So Why Not Pay It Some Attention?

DongKook Pharmaceutical Co., Ltd.'s (KOSDAQ:086450) Stock Is Going Strong: Is the Market Following Fundamentals?

Feb 14
DongKook Pharmaceutical Co., Ltd.'s (KOSDAQ:086450) Stock Is Going Strong: Is the Market Following Fundamentals?

DongKook Pharmaceutical (KOSDAQ:086450) Seems To Use Debt Quite Sensibly

Feb 01
DongKook Pharmaceutical (KOSDAQ:086450) Seems To Use Debt Quite Sensibly

DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Shares Could Be 47% Below Their Intrinsic Value Estimate

Jan 19
DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Shares Could Be 47% Below Their Intrinsic Value Estimate

The Attractive Combination That Could Earn DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) A Place In Your Dividend Portfolio

Jan 06
The Attractive Combination That Could Earn DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) A Place In Your Dividend Portfolio

DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Dec 24
DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

With EPS Growth And More, DongKook Pharmaceutical (KOSDAQ:086450) Is Interesting

Dec 21
With EPS Growth And More, DongKook Pharmaceutical (KOSDAQ:086450) Is Interesting

What Kind Of Investors Own Most Of DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)?

Dec 08
What Kind Of Investors Own Most Of DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)?

The DongKook Pharmaceutical (KOSDAQ:086450) Share Price Is Up 177% And Shareholders Are Boasting About It

Nov 23
The DongKook Pharmaceutical (KOSDAQ:086450) Share Price Is Up 177% And Shareholders Are Boasting About It

Previsiones de crecimiento de beneficios e ingresos

KOSDAQ:A086450 - Estimaciones futuras de los analistas y datos financieros pasados (KRW Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/2026981,60072,300N/A73,8001
12/31/2025893,80073,10075,00076,1502
12/31/2024810,50055,30054,20070,8001
12/31/2023730,99447,1752,20341,793N/A
9/30/2023709,54347,474-4,83438,961N/A
6/30/2023692,79447,1576,55041,667N/A
3/31/2023676,77253,2307,39043,763N/A
12/31/2022661,64752,896-11,06440,909N/A
9/30/2022645,74458,943-2,67345,738N/A
6/30/2022631,06555,611-12,49448,082N/A
3/31/2022615,97450,919-16,17049,477N/A
12/31/2021594,19350,345-5,02244,654N/A
9/30/2021585,74043,9451,63947,422N/A
6/30/2021588,36052,48425,34360,698N/A
3/31/2021572,39154,5155,61648,930N/A
12/31/2020559,10355,92517,81459,108N/A
9/30/2020544,68563,50219,85965,202N/A
6/30/2020520,46961,56913,24459,474N/A
3/31/2020502,39060,36038,67968,633N/A
12/31/2019482,28056,31244,37769,483N/A
9/30/2019456,23053,797-13,02360,123N/A
6/30/2019436,29350,618-28,59849,945N/A
3/31/2019418,58349,157-40,69532,790N/A
12/31/2018400,80746,949-42,32433,209N/A
9/30/2018391,80145,6958,92530,618N/A
6/30/2018378,38842,87224,48036,546N/A
3/31/2018366,90541,69525,78341,149N/A
12/31/2017354,76839,60216,77228,659N/A
9/30/2017342,29338,070N/A28,869N/A
6/30/2017330,62939,996N/A28,465N/A
3/31/2017320,34940,421N/A34,431N/A
12/31/2016309,69040,660N/A39,412N/A
9/30/2016302,00738,101N/A42,036N/A
6/30/2016292,76035,192N/A40,984N/A
3/31/2016275,17430,488N/A36,877N/A
12/31/2015259,93027,426N/A27,143N/A
9/30/2015244,76623,139N/A20,752N/A
6/30/2015234,68621,380N/A16,372N/A
3/31/2015228,19720,811N/A17,437N/A
12/31/2014226,01421,098N/A22,737N/A
9/30/2014224,39118,107N/A22,406N/A
6/30/2014220,61218,859N/A21,157N/A
3/31/2014218,09417,552N/A20,954N/A
12/31/2013213,08616,764N/A19,860N/A
9/30/2013206,33222,030N/A19,471N/A
6/30/2013201,69122,205N/A23,102N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (16.2% al año) de A086450 es superior a la tasa de ahorro (2.4%).

Beneficios vs. Mercado: Se prevé que los beneficios (16.2% al año) de A086450 crezcan menos que el mercado KR (29.7% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de A086450 crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (9.7% al año) de A086450 crezcan más rápidamente que los del mercado KR (8.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 9.7% al año) de A086450 crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de A086450 sea baja dentro de 3 años (10.6%).

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y